Risk factors for resignation from work after starting infertility treatment among Japanese women: Japan-Female Employment and Mental health in Assisted reproductive technology (J-FEMA) study ============================================================================================================================================================================================== * Yuya Imai * Motoki Endo * Keiji Kuroda * Kiyohide Tomooka * Yuko Ikemoto * Setsuko Sato * Kiyomi Mitsui * Yuito Ueda * Gautam A Deshpande * Atsushi Tanaka * Rikikazu Sugiyama * Koji Nakagawa * Yuichi Sato * Yasushi Kuribayashi * Atsuo Itakura * Satoru Takeda * Takeshi Tanigawa ## Abstract **Objective** To elucidate the risk factors associated with resignation from work of Japanese women undergoing infertility treatment. **Methods** A total of 1727 female patients who attended a private fertility clinic in Japan participated in the Japan-Female Employment and Mental health in Assisted reproductive technology study. Questions related to demographic, clinical and socioeconomic characteristics were employed in the questionnaire. Out of the 1727 patients, 1075 patients who were working at the time of initiating infertility treatment and felt infertility treatment incompatible with work were included in the analysis. Risk factors for resignation were assessed by using multivariable logistic regression models. **Results** Among 1075 working women who started infertility treatment, 179 (16.7%) subsequently resigned. Multivariable-adjusted ORs for resignation in those with lower educational background and infertility for ≥2 years were 1.58 (95% CI: 1.07 to 2.34) and 1.82 (95% CI: 1.15 to 2.89), respectively. The OR for resignation in non-permanent workers undergoing infertility treatment was 2.65 (95% CI: 1.61 to 4.37). While experiencing harassment in the workplace approached significance, lack of support from the company was significantly associated with resignation after starting infertility treatment, with ORs of 1.71 (95% CI: 0.98 to 2.99) and 1.91 (95% CI: 1.28 to 2.86), respectively. **Conclusion** One-sixth of women resigned after starting infertility treatments. It was found that factors related to education, infertility duration and work environment were significantly associated with resignation. Reducing the physical and psychological burden endured by women, for example, by increasing employer-provided support, is vitally important in balancing infertility treatment with maintenance of work life. * occupational health practice * obs and gynae * cross sectional studies * women * sickness absence ### Key messages #### What is already known about this subject? * Psychological distress brought about by infertility treatment is related to absence from work. * The difficulties of combining work and infertility treatment are associated with job insecurity. * Few preliminary studies show risk factors for resignation after starting infertility treatment despite continued high treatment expenses until the end of treatment. #### What are the new findings? * Lower educational background, longer duration of infertility, non-permanent worker, harassment experience in the workplace and lack of support within the company were identified as risk factors for resignation after initiating infertility treatment. #### How might this impact on policy or clinical practice in the foreseeable future? * Prior to infertility treatment, providing special care such as infertility treatment leave, in addition to psychological support, to those who have these risk factors may reduce the tendency of resigning from work. * This finding may contribute to policy development to secure a healthy work life for patients undergoing infertility treatment. ## Introduction In the USA, Europe and high-income Asian counties, the number of women receiving treatments for infertility has increased in the recent years.1–3 This phenomenon is largely understood in the context of increasing age at marriage and childbearing, as well as increasing attainment of higher education among women in the last half-century.4–6 Nonetheless, ovarian function declines with age, with peak fertility occurring in the early 20s and decreasing at 32 years, with rapid subsequent declines in ovarian reserve from 35 to 38 years.7 Gynaecological diseases that alter conception and successful pregnancy, including endometriosis and uterine myoma, also increase with the cumulative number of ovulations and menstruations. Given the complex interplay between these numerous social and biological factors, when women wish to have children later after marriage, conception and successful pregnancy are more difficult. Since the first in vitro fertilisation (IVF) baby in the UK in 1978,4 treatment for infertility has improved remarkably over the last several decades. Infertility treatments typically consist of either the timing method, artificial insemination with husband’s semen or assisted reproductive technology (ART), which includes IVF and intracytoplasmic sperm injection (ICSI).8 In Japan, there has been a decline in the number of births to about half in the last 40 years, with 1 708 643 babies born in 1978 to 918 400 babies in 2018. Despite this, approximately 1 in 5.5 Japanese couples opts for infertility treatment and this number continues to increase.9 The highest number of ART cases in the world is currently yielded in Japan,2 3 with 447 790 cycles and 54 110 neonates—about 1 in 18.1 neonates born in 2016 were conceived via ART treatment.3 While more women are choosing to undergo infertility treatment, balancing infertility treatment with work is affected by various factors, including demographic, clinical and socioeconomic characteristics.2 10–12 Maintaining employment can be challenging for women undergoing infertility treatments with regard to physical, mental and economical impacts. Notably, infertility treatment, especially ART procedures, may require frequent and sudden clinic visits depending on the individual’s menstruation cycle—and as such, some women consequently decide to resign from their work despite continued high expenses until treatment success.13 Moreover, ART is not covered by the Japanese National Health Insurance, and this adds further substantial out-of-pocket expenses.14 The Japanese Government, Ministry of Health, Labour and Welfare, developed a financial subsidy programme to help reduce the economical impact on a specific infertility treatment including examinations.15 16 As it varies among local government policies and largely depends on the contents of applicable procedures, the subsidy programmes benefit 150 000 Japanese yen (JPY) (approximately 1100 British pounds (GBP), converted with the average exchange rate in August 2020: 139.3 JPY/GBP) at maximum per one cycle of an IVF or ICSI, which generally costs JPY300 000–500 000 (2200–3600 GBP) in Japan. However, it is also restricted by frequency of treatments (≤6 times), annual household incomes (